Your browser doesn't support javascript.
loading
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio, Chiara; Köhler, Jens; Zhou, Zhi-Wei; Wang, Haiyun; Paranal, Raymond; Li, Jiaqi; Capelletti, Marzia; Caffarra, Cristina; Li, Shuai; Lv, Qi; Gondi, Sudershan; Hunter, John C; Lu, Jia; Chiarle, Roberto; Santamaría, David; Westover, Kenneth D; Jänne, Pasi A.
Affiliation
  • Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: chiara_ambrogio@dfci.harvard.edu.
  • Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Zhou ZW; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Wang H; School of Life Science and Technology, Tongji University, 200092 Shanghai, China.
  • Paranal R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Li J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Capelletti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Caffarra C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Lv Q; School of Life Science and Technology, Tongji University, 200092 Shanghai, China.
  • Gondi S; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Hunter JC; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Lu J; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Chiarle R; Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Molecular Biotechnology and Health Science, University of Torino, 10126, Italy.
  • Santamaría D; University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, F-33600 Pessac, France.
  • Westover KD; Departments of Biochemistry and Radiation Oncology, the University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: kenneth.westover@utsouthwestern.edu.
  • Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: pasi_janne@dfci.harvard.edu.
Cell ; 172(4): 857-868.e15, 2018 02 08.
Article in En | MEDLINE | ID: mdl-29336889
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Mutation, Missense / MAP Kinase Kinase Kinases / Enzyme Inhibitors / Protein Multimerization / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Mutation, Missense / MAP Kinase Kinase Kinases / Enzyme Inhibitors / Protein Multimerization / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Journal: Cell Year: 2018 Type: Article